Peptide Pepe
PeptidePepeResearch Lab
HomeDatabasePricingNewsMemes
🔬 RUOResearch Only
LABORATORY RESEARCH USE ONLY — This compound is NOT for human consumption, veterinary use, or therapeutic applications.
Weight LossMetabolic Research⭐ Featured🔬 RUO

Tirzepatide

Molecular Data

Formula

C225H348N48O68

Mol. Weight

4813.45 Da

CAS Number

2023788-19-2

Purity

≥98% (HPLC)

Appearance

White lyophilized powder

Storage

-20°C, desiccated

Amino Acid Sequence

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(γGlu-C20 diacid)-Ile-Ala-Gln-Glu-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln

Research Overview
Tirzepatide is a novel dual GIP/GLP-1 receptor agonist peptide representing a new class of research compounds. This 39-amino acid synthetic peptide was designed with a C-20 fatty di-acid moiety enabling once-weekly research protocols. Its unique dual agonism makes it an invaluable tool for studying the interplay between GIP and GLP-1 receptor signaling pathways. Developed by Eli Lilly, tirzepatide has rapidly become one of the most studied peptides in metabolic research. Thinking Pepe approves of this dual-action compound. 🐸
Mechanism of Action
Activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors simultaneously, producing synergistic effects on metabolic pathways in preclinical models.
Research Applications
Dual incretin pathway research, metabolic syndrome modeling, adipose tissue biology, hepatic lipid metabolism studies, pancreatic beta-cell function analysis.
Key Research Findings
Dual receptor binding studies confirm balanced GIP/GLP-1 agonism (Coskun et al., 2018, Mol Metab). In vitro cAMP assays demonstrate biased agonism at the GIP receptor (Willard et al., 2020, Nat Commun). Research shows enhanced beta-cell function markers in pancreatic islet models (Thomas et al., 2021, Lancet). Comparative receptor binding affinity studies vs mono-agonists (Samms et al., 2021, Trends Endocrinol Metab). Pharmacokinetic analysis reveals 5-day half-life profile (Urva et al., 2022, Clin Pharmacokinet).
References & Citations
PMID: 30473063, PMID: 32764681, PMID: 34170647, PMID: 33744556, PMID: 35064925
MANDATORY DISCLAIMER: Tirzepatide as referenced on this page is strictly for in-vitro laboratory research and forensic applications only. It is NOT for human consumption, veterinary use, diagnostic purposes, therapeutic applications, or any form of bodily introduction. Any reference to research outcomes pertains exclusively to controlled laboratory settings. Researchers must comply with all applicable local, state, and federal regulations.
Peptide Pepe
PeptidePepe

Rare Peptides for Rare Pepes 🐸

DatabasePricingStacks$PEPPYBlogGlossaryFAQCompliance
MANDATORY DISCLAIMER: All compounds and peptides referenced on peptidepepe.com are strictly for in-vitro laboratory research and forensic applications only. They are NOT for human consumption, veterinary use, diagnostic purposes, therapeutic applications, or any form of bodily introduction. Any reference to "subjects" pertains exclusively to laboratory research settings. $PEPPY is a utility-free meme token for community engagement only.

💤 Rest anon, the peptides are working... 🐸❄️

© 2026 PeptidePepe.com — Rare Peptides for Rare Pepes. All research data for educational purposes only.

HomeDatabasePricingNewsMemes

Laboratory Research Use Only

All compounds, peptides, and research materials referenced on peptidepepe.com are strictly for in-vitro laboratory research and forensic applications only.These products are NOT intended for human consumption, veterinary use, diagnostic purposes, therapeutic applications, or any form of bodily introduction.By proceeding, you confirm that you are a qualified researcher or represent a legitimate research institution, and you agree to use all information on this platform exclusively for lawful research purposes.